Shandong Weigao Blood Purification Products Co., Ltd. (SHA:603014)
China · Delayed Price · Currency is CNY 30.79
-0.34 (-1.09%)
At close: Sep 11, 2026
SHA:603014 Revenue
Shandong Weigao Blood Purification Products had revenue of 853.98M CNY in the quarter ending June 30, 2026, a decrease of -1.69%. This brings the company's revenue in the last twelve months to 3.76B, up 0.52% year-over-year. In the year 2025, Shandong Weigao Blood Purification Products had annual revenue of 3.77B with 4.57% growth.
Revenue (ttm)
3.76B
Revenue Growth
+0.52%
P/S Ratio
3.42
Revenue / Employee
n/a
Employees
3,734
Market Cap
12.86B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.77B | 164.70M | 4.57% |
| Dec 31, 2024 | 3.60B | 71.87M | 2.03% |
| Dec 31, 2023 | 3.53B | 106.03M | 3.09% |
| Dec 31, 2022 | 3.43B | 515.59M | 17.71% |
| Dec 31, 2021 | 2.91B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Autobio Diagnostics | 4.22B |
| Cofoe Medical Technology | 3.96B |
| Double Medical Technology | 2.73B |
| Qingdao Haier Biomedical Co.,Ltd | 2.43B |
| Jafron Biomedical | 1.91B |
| MeHow Innovative | 1.71B |
| Shandong Weigao Orthopaedic Device | 1.49B |
| Shanghai MicroPort Endovascular MedTech | 1.43B |